The purpose of this study is to look at the long term effects and safety of Premenopausal Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids, who have already participated in the first study M12-815. Subjects will currently be enrolled in the first study.
This study is try to understand current patients with fibroids and there choices for management. We will follow women through their journey and obtain patient reported outcomes, through questionnaire's, following their current therapies for Uterine Fibroids, including symptoms, quality of life, work productivity impact, and satisfaction.
The purpose of this study is to test how well patients with heavy menstrual bleeding associated with uterine fibroids respond to a medication called Elagolix. It aims to possibly find out how heavy menstrual bleeding associated with uterine fibroids and related conditions develop and progress and how they can be diagnosed, monitored, or treated, possibly develop tests to identify which patients are likely to have different diseases, respond to the study drug or drugs of the same or similar class, or to predict the progression of the heavy menstrual bleeding associated with uterine fibroids, and to possibly develop new therapies, research methods, or technologies. Participation in the study will last approximately 20 months.